A Phase I, Open-Label, Multiple Dose, Dose-escalation Study of the Anti- CTLA-4 Monoclonal Antibody CS1002 in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2018
At a glance
- Drugs CS-1002 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors CStone Pharmaceuticals
- 04 May 2018 Status changed from planning to recruiting, according to a CStone Pharmaceuticals media release.
- 04 May 2018 According to a CStone Pharmaceuticals media release, first patient has been dosed in this trial in Australia. This trial is being led by Professor Dusan Kotasek of the Ashford Cancer Centre Researchand.
- 08 Jan 2018 New trial record